Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vaccine shield transplant patients from shingles?

NCT ID NCT05604911

Knowledge-focused Sponsor: Susanne Dam Nielsen, MD, DMSc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study looks at how the immune system of kidney transplant patients responds to the shingles vaccine and to natural shingles infection. Researchers will track antibody and T-cell levels over time in patients who have had a transplant or are on the waiting list. The goal is to understand these immune responses better, which could lead to improved ways to prevent and treat shingles in this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Shingrix® (recombinant varicella-zoster virus vaccine)
What this could lead to
If successful, this could lead to better vaccination strategies and improved prevention of shingles in kidney transplant patients.
What could go wrong
This is an observational study, so it won't directly test new treatments. Results may not lead to immediate changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

280 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Kidney transplant recipients transplanted after 2019-01-01 and kidney transplant candidates followed at Copenhagen University Hospital - Rigshospitalet, Aarhus University Hospital and Odense University Hospital who has been offered Shingrix® vaccination will be invited to participate

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Kidney transplant recipient transplanted after 2019-01-01 OR on the kidney transplant waitlist * Has been offered Shingrix® vaccination Exclusion Criteria: * Lack of informed consent * Inability to understand the study information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant candidate (end-stage kidney disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chickenpox end stage renal failure Vaccine-Preventable Diseases varicella zoster infection Varicella Zoster Virus Infection herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant; complications Vaccine-preventable diseases Varicella zoster virus infection

Contacts and locations

Locations

  • Department of Health Technology, Technical University of Denmark

    Lyngby, 2800, Denmark

  • Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet

    Copenhagen, 2100, Denmark

  • Department of Nephrology, Aarhus University Hospital

    Aarhus, Denmark

  • Department of Nephrology, Copehagen University Hospital - Rigshospitalet

    Copenhagen, 2100, Denmark

  • Department of Nephrology, Odense University Hospital

    Odense, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.